School of Medicine Publications and Presentations

Document Type

Article

Publication Date

2-2023

Abstract

Highlights

  • The trends of pancreatic cancer (PanCa) incidence and mortality are on rising pattern, and it will a second leading cause of cancer related deaths by 2030.
  • Approximately 85–90% PanCa are pancreatic ductal adenocarcinoma (PDAC), which is one of the most challenging and aggressive malignancy.
  • PDAC exhibits with grim prognosis as mortality rate is very close to the incidence due lack of early detection methods and effective therapeutic regimen.
  • Our team has identified a novel oncogenic protein, carcinoembryonic antigen-related cell adhesion molecule 7 (CEACAM7), that can be useful for early PDAC diagnosis and predictor of patient survival.
  • We also observed an increase of CEACAM7 expression in PDAC cell line panel model. However, poorly differentiated, and normal cell lines did not show any expression.
  • Commercially available human tissue analysis also strengthened our data by showing strong and positive IHC staining in early-stage tumors.

Abstract

Background

The trends of pancreatic cancer (PanCa) incidence and mortality are on rising pattern, and it will be a second leading cause of cancer related deaths by 2030. Pancreatic ductal adenocarcinoma (PDAC), major form of PanCa, exhibits a grim prognosis as mortality rate is very close to the incidence rate, due to lack of early detection methods and effective therapeutic regimen. Considering this alarming unmet clinic need, our team has identified a novel oncogenic protein, carcinoembryonic antigen-related cell adhesion molecule 7 (CEACAM7), that can be useful for spotting early events of PDAC.

Methodology

This study includes bioinformatics pre-screening using publicly available cancer databases followed by molecular biology techniques in PDAC progressive cell line panel and human tissues to evaluate CEACAM7 expression in early events of pancreatic cancer.

Results

PanCa gene and protein expression analysis demonstrated the significantly higher expression of CEACAM7 in PDAC, compared to other cancers and normal pancreas. Overall survival analysis demonstrated an association between the higher expression of CEACAM7 and poor patients’ prognosis with high hazard ratio. Additionally, in a performance comparison analysis CEACAM7 outperformed S100A4 in relation to PDAC. We also observed an increase of CEACAM7 in PDAC cell line panel model. However, poorly differentiated, and normal cell lines did not show any expression. Human tissue analysis also strengthened our data by showing strong and positive IHC staining in early-stage tumors.

Conclusion

Our observations clearly cite that CEACAM7 can serve as a potential early diagnostic and/or prognostic marker of PDAC and may also potentiate the sensitivity of the existing biomarker panel of PDAC. However, further studies are warranted to determine its clinical significance.

Comments

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Publication Title

Journal of advanced research

DOI

10.1016/j.jare.2023.02.013

Academic Level

faculty

Mentor/PI Department

Immunology and Microbiology

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.